Table 2. Relationship between sMFS frailty screening scale in univariate analyses with demographic characteristics, chronic diseases, geriatric syndromes, 90-day all-cause mortality, and length of stay.
sMFS≥3 (n=75) 89.3 % | sMFS<3 (n=9) 10.7% | Total (n=84) 100% | p-value | ||
---|---|---|---|---|---|
Age | 79.2 ±7.5 | 71.5 ± 5.1 | 78.3±7.6 | 0.004Θ | |
Gender | |||||
Male | 25 (33.3%) | 6 (66.7%) | 31 (36.9%) | 0.050 | |
Female | 50 (66.7%) | 3 (33.3%) | 53 (63.1%) | ||
Chronic disease (n, %) | |||||
CHF | 22 (29.3%) | 1 (11.1%) | 23 (27.4%) | 0.247 | |
CKF | 14 (18.7%) | 5 (55.6%) | 19 (22.6%) | 0.012Θ | |
COPD | 8 (10.7%) | 1 (11.1%) | 9 (10.7%) | 0.968 | |
DM | 32 (42.7%) | 3 (33.3%) | 35 (41.7%) | 0.592 | |
Dementia | 20 (26.7%) | 0 (0%) | 20 (23.8%) | 0.076 | |
Depression | 14 (18.7%) | 0 (0%) | 14 (16.7%) | 0.156 | |
HT | 57 (76%) | 6 (66.7%) | 63 (75%) | 0.541 | |
Geriatric syndromes (n, %) | |||||
Falls | 42 (56%) | 3 (33.3%) | 45 (53.6%) | 0.198 | |
Undernutrition (MN+MNR)┴ | 72 (97.3%) | 9 (100%) | 81 (97.6%) | 0.618 | |
Frailty fracture in last year┴ | 10 (13.5%) | 1 (11.1%) | 11 (13.3%) | 0.841 | |
Urinary incontinence | 56 (74.7%) | 8 (88.9%) | 64 (76.2%) | 0.344 | |
Sleep disorders× | 44 (58.7%) | 5 (55.6%) | 49 (59.8%) | 0.785 | |
Polypharmacy (n, %) | 71 (94.7%) | 8 (88.9%) | 79 (94%) | 0.489 | |
Number of chronic drugs | 10.2 ±3.8 | 7.6 ±3.7 | 10±3.9 | 0.058 | |
Number of chronic diseases | 4.4±2.2 | 3.7± 1.5 | 4.3±2.1 | 0.367 | |
ADL* | 5 (0-6) | 6 (5-6) | 5 (0-6) | 0.008Θ | |
IADL* | 3 (0-8) | 8 (7-8) | 4 (0-8) | <0.001Θ | |
Length of stay* | 15 (1-158) | 16 (4-50) | 15.5 (1-158) | 0.862 | |
90-day mortality (days) | 16 (21.3%) | 0 (0%) | 16 (19%) | 0.849 |
ADL: activities of daily living
CHF: congestive heart failure
CKF: chronic kidney failure
COPD: chronic obstructive pulmonary disease
DM: diabetes mellitus
HT: hypertension
IADL: ınstrumental activities of daily living
MFS: Simpler Modified Fried Scale
MN: malnutrition
MNR: malnutrition risk
Given data as median.
Significant p-values.
Marked data include 83 participants.
Marked data include 82 participants.